RCS - Shield Therapeutics - Investor presentation

Shield TherapeuticsAnnouncement

21/09/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210921:nRSU3576Ma&default-theme=true

RNS Number : 3576M  Shield Therapeutics PLC  21 September 2021

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

 

Investor presentation

Hardman & Co Life Sciences Investor Forum

 

London, UK, 21 September, 2021:  Shield Therapeutics plc (LSE: STX), a
commercial stage, pharmaceutical company with a focus on addressing iron
deficiency with its lead product Feraccru®/Accrufer® (ferric maltol),
announces Greg Madison, CEO of Shield, will be presenting at the Hardman &
Co Life Sciences Investor Forum on Thursday 23 September 2021.

 

The webinar event will begin at 17:00 (BST) and investors can register to
attend here: https://hardman-co.com/p/49CL-HU2/join-our-webinar
(https://hardman-co.com/p/49CL-HU2/join-our-webinar)

 

No new material information will be disclosed at this event and the
presentation will be made available on the Company website shortly after the
event.

 

For further information please contact:

 

 Shield Therapeutics plc                                                                             www.shieldtherapeutics.com (http://www.shieldtherapeutics.com/)
 Greg Madison, CEO                                                                                   +44 (0) 191 511 8500
 Hans-Peter Rudolf, CFO

 Nominated Adviser and Joint Broker
 Peel Hunt LLP
 James Steel/Christopher Golden                                                                      +44 (0)20 7418 8900

 Joint Broker

 finnCap Ltd                                                                                         +44 (0)20 7220 0500

 Geoff Nash/Alice Lane/George
 Dollemore

 Financial PR & IR Advisor
 Walbrook PR                                                                                         +44 (0)20 7933 8780 or shield@walbrookpr.com (mailto:shield@walbrookpr.com)
 Paul McManus/Lianne Cawthorne

 

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric
maltol), a novel, stable, non-salt based oral therapy for adults with iron
deficiency with or without anaemia.

 

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the
United States, European Union, UK, Switzerland and Australia and has exclusive
IP rights until the mid-2030s. Accrufer® has been launched in the US in July
2021 through a highly experienced sales and marketing team. Feraccru® is
already being commercialised in the UK and European Union by Norgine B.V., who
also have the marketing rights in Australia and New Zealand. Shield also has
an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co.,
Ltd., for the development and commercialisation of Feraccru®/Accrufer® in
China, Hong Kong, Macau and Taiwan.

 

For more information, please visit www.shieldtherapeutics.com. Follow Shield
on Twitter @ShieldTx

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALMMITMTATBBB